Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis

Dalibor Lecian, Hana Demova, Alena Lodererova, Jana Zdychova, Hana Kluckova, Vladimir Teplan, Ludek Voska, Radko Komers

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background/Aims: In addition to their lipid-lowering effects, HMG-CoA reductase inhibitors (statins) induce a variety of pleiotropic actions that have been recently studied in the area of cardiovascular and renal protection. In the present studies we sought to determine whether statins retain beneficial effects in the experimental model of NO deficiency achieved by chronic administration of a pressor dose of L-arginine analogue N-nitro-L-arginine- methyl ester (L-NAME). Methods: To address this issue, blood pressure (BP), renal function (GFR), and albuminuria were determined in rats treated for 4 weeks with L-NAME, L-NAME + atorvastatin (ATO), and in untreated controls. In addition, renal cortical protein expression of caveolin 1 (CAV1), vascular endothelial growth factor (VEGF), and activity of RhoA were also determined. Results: L-NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria as compared to control animals. Co-administration of ATO with L-NAME normalized albuminuria and prevented decreases in GFR in L-NAME rats without having an impact on pressor effects of L-NAME. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. Conclusion: Treatment with ATO exerts early nephroprotective effects in the NO-deficient model of hypertension. These effects could be mediated by amelioration of VEGF expression and reduction of RhoA activity.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalKidney and Blood Pressure Research
Volume29
Issue number3
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl CoA Reductases
Arginine
Nitric Oxide
Kidney
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Albuminuria
Vascular Endothelial Growth Factor A
Caveolin 1
Caveolins
Blood Pressure
arginine methyl ester
Theoretical Models
Hypertension
Lipids
Atorvastatin Calcium

Keywords

  • Albuminuria
  • Atorvastatin
  • Caveolin 1
  • Hypertension
  • N-nitro-L-arginine-methyl ester
  • Nitric oxide inhibition
  • RhoA
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Lecian, D., Demova, H., Lodererova, A., Zdychova, J., Kluckova, H., Teplan, V., ... Komers, R. (2006). Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney and Blood Pressure Research, 29(3), 135-143. https://doi.org/10.1159/000094988

Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. / Lecian, Dalibor; Demova, Hana; Lodererova, Alena; Zdychova, Jana; Kluckova, Hana; Teplan, Vladimir; Voska, Ludek; Komers, Radko.

In: Kidney and Blood Pressure Research, Vol. 29, No. 3, 10.2006, p. 135-143.

Research output: Contribution to journalArticle

Lecian, D, Demova, H, Lodererova, A, Zdychova, J, Kluckova, H, Teplan, V, Voska, L & Komers, R 2006, 'Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis', Kidney and Blood Pressure Research, vol. 29, no. 3, pp. 135-143. https://doi.org/10.1159/000094988
Lecian, Dalibor ; Demova, Hana ; Lodererova, Alena ; Zdychova, Jana ; Kluckova, Hana ; Teplan, Vladimir ; Voska, Ludek ; Komers, Radko. / Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. In: Kidney and Blood Pressure Research. 2006 ; Vol. 29, No. 3. pp. 135-143.
@article{e6b7b99017ea4e52a61b4f020db4beed,
title = "Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis",
abstract = "Background/Aims: In addition to their lipid-lowering effects, HMG-CoA reductase inhibitors (statins) induce a variety of pleiotropic actions that have been recently studied in the area of cardiovascular and renal protection. In the present studies we sought to determine whether statins retain beneficial effects in the experimental model of NO deficiency achieved by chronic administration of a pressor dose of L-arginine analogue N-nitro-L-arginine- methyl ester (L-NAME). Methods: To address this issue, blood pressure (BP), renal function (GFR), and albuminuria were determined in rats treated for 4 weeks with L-NAME, L-NAME + atorvastatin (ATO), and in untreated controls. In addition, renal cortical protein expression of caveolin 1 (CAV1), vascular endothelial growth factor (VEGF), and activity of RhoA were also determined. Results: L-NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria as compared to control animals. Co-administration of ATO with L-NAME normalized albuminuria and prevented decreases in GFR in L-NAME rats without having an impact on pressor effects of L-NAME. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. Conclusion: Treatment with ATO exerts early nephroprotective effects in the NO-deficient model of hypertension. These effects could be mediated by amelioration of VEGF expression and reduction of RhoA activity.",
keywords = "Albuminuria, Atorvastatin, Caveolin 1, Hypertension, N-nitro-L-arginine-methyl ester, Nitric oxide inhibition, RhoA, Vascular endothelial growth factor",
author = "Dalibor Lecian and Hana Demova and Alena Lodererova and Jana Zdychova and Hana Kluckova and Vladimir Teplan and Ludek Voska and Radko Komers",
year = "2006",
month = "10",
doi = "10.1159/000094988",
language = "English (US)",
volume = "29",
pages = "135--143",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis

AU - Lecian, Dalibor

AU - Demova, Hana

AU - Lodererova, Alena

AU - Zdychova, Jana

AU - Kluckova, Hana

AU - Teplan, Vladimir

AU - Voska, Ludek

AU - Komers, Radko

PY - 2006/10

Y1 - 2006/10

N2 - Background/Aims: In addition to their lipid-lowering effects, HMG-CoA reductase inhibitors (statins) induce a variety of pleiotropic actions that have been recently studied in the area of cardiovascular and renal protection. In the present studies we sought to determine whether statins retain beneficial effects in the experimental model of NO deficiency achieved by chronic administration of a pressor dose of L-arginine analogue N-nitro-L-arginine- methyl ester (L-NAME). Methods: To address this issue, blood pressure (BP), renal function (GFR), and albuminuria were determined in rats treated for 4 weeks with L-NAME, L-NAME + atorvastatin (ATO), and in untreated controls. In addition, renal cortical protein expression of caveolin 1 (CAV1), vascular endothelial growth factor (VEGF), and activity of RhoA were also determined. Results: L-NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria as compared to control animals. Co-administration of ATO with L-NAME normalized albuminuria and prevented decreases in GFR in L-NAME rats without having an impact on pressor effects of L-NAME. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. Conclusion: Treatment with ATO exerts early nephroprotective effects in the NO-deficient model of hypertension. These effects could be mediated by amelioration of VEGF expression and reduction of RhoA activity.

AB - Background/Aims: In addition to their lipid-lowering effects, HMG-CoA reductase inhibitors (statins) induce a variety of pleiotropic actions that have been recently studied in the area of cardiovascular and renal protection. In the present studies we sought to determine whether statins retain beneficial effects in the experimental model of NO deficiency achieved by chronic administration of a pressor dose of L-arginine analogue N-nitro-L-arginine- methyl ester (L-NAME). Methods: To address this issue, blood pressure (BP), renal function (GFR), and albuminuria were determined in rats treated for 4 weeks with L-NAME, L-NAME + atorvastatin (ATO), and in untreated controls. In addition, renal cortical protein expression of caveolin 1 (CAV1), vascular endothelial growth factor (VEGF), and activity of RhoA were also determined. Results: L-NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria as compared to control animals. Co-administration of ATO with L-NAME normalized albuminuria and prevented decreases in GFR in L-NAME rats without having an impact on pressor effects of L-NAME. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. Conclusion: Treatment with ATO exerts early nephroprotective effects in the NO-deficient model of hypertension. These effects could be mediated by amelioration of VEGF expression and reduction of RhoA activity.

KW - Albuminuria

KW - Atorvastatin

KW - Caveolin 1

KW - Hypertension

KW - N-nitro-L-arginine-methyl ester

KW - Nitric oxide inhibition

KW - RhoA

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33750161138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750161138&partnerID=8YFLogxK

U2 - 10.1159/000094988

DO - 10.1159/000094988

M3 - Article

C2 - 16899993

AN - SCOPUS:33750161138

VL - 29

SP - 135

EP - 143

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 3

ER -